Matteo Fassan

Prof. Matteo Fassan

University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
GVGeorgios Vlachogiannis
Georgios Vlachogiannis
SHSomaieh Hedayat
Somaieh Hedayat
AVAlexandra Vatsiou
Alexandra Vatsiou
YJYann Jamin
Yann Jamin
JFJavier Fernández-Mateos
Javier Fernández-Mateos
NVNicola Valeri
Nicola Valeri
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920

15 February 2017 in Nature
Verified
Journal Article
Closed access
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ASAldo Scarpa
Aldo Scarpa
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
VCVincenzo Corbo
Vincenzo Corbo
SGSean M. Grimmond
Sean M. Grimmond

3 November 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YJYuchen Jiao
Yuchen Jiao
TPTimothy M Pawlik
Timothy M Pawlik
RARobert A Anders
Robert A Anders
FSFlorin M Selaru
Florin M Selaru
MSMirte M Streppel
Mirte M Streppel
LWLaura D Wood
Laura D Wood

1 September 2007 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
FGFedra Gottardo
Fedra Gottardo
CLChang Gong Liu
Chang Gong Liu
MFManuela Ferracin
Manuela Ferracin
George CalinGeorge Calin
George Calin
Matteo FassanMatteo Fassan
Matteo Fassan
RBRaffaele Baffa
Raffaele Baffa

1 September 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ESElizabeth C. Smyth
Elizabeth C. Smyth
AWAndrew Wotherspoon
Andrew Wotherspoon
CPClare Peckitt
Clare Peckitt
DGDavid Gonzalez
David Gonzalez
SHSanna Hulkki-Wilson
Sanna Hulkki-Wilson
DCDavid Cunningham
David Cunningham
Gastric cancer is the fifth most common cancer and the third most common cause of cancer-related death globally.1 In Western countries, patients with operable gastric or gastroesophageal adenocarcinoma frequently undergo neoadjuvant or perioperative chemotherapy before surgical resection.2,3 This adjunctive chemotherapy is associated with a modest benefit in terms of overall survival (OS) compared with surgery alone but also with toxic effects, including neutropenia and thromboembolic disease. Unfortunately, after optimal multimodality therapy, approximately half of patients undergoing resection will relapse and die of their cancer. There are no validated prognostic biomarkers for patients with gastroesophageal cancer who receive neoadjuvant treatment, and current patient selection is based purely on preoperative radiologic staging.

1 June 2009 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
RBRaffaele Baffa
Raffaele Baffa
Matteo FassanMatteo Fassan
Matteo Fassan
Stefano VoliniaStefano Volinia
Stefano Volinia
BOBrian O'HAra
Brian O'HAra
CLChang‐Gong Liu
Chang‐Gong Liu
ARAnne Rosenberg
Anne Rosenberg